Dihydroergotamine mesylate is under clinical development by Satsuma Pharmaceuticals and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Dihydroergotamine mesylate’s likelihood of approval (LoA) and phase transition for Migraine took place on 02 May 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Dihydroergotamine mesylate Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Dihydroergotamine mesylate overview

Dihydroergotamine mesylate (STS-101, TO-2070) is under development for the treatment of acute migraine. The drug candidate is an ergot alkaloid that acts on 5-HT1D antimigraine receptors. It is administered through nasal dry powder drug delivery system. TO-2070 is based on a nasal powder drug delivery technology that combines a muco-adhesive drug carrier with a proprietary nasal powder drug delivery device.

Satsuma Pharmaceuticals overview

Satsuma Pharmaceuticals (Satsuma) is biopharmaceutical company. It develops novel therapies for neurological diseases. It is investigating its lead pipeline candidate STS101 is a proprietary investigational drug-device combination product which enables intranasal administration of the anti-migraine drug, dihydroergotamine mesylate (DHE). The company is funded by RA Capital Management, TPG Biotech, Shin Nippon Biomedical Laboratories, Osage University Partners, CAM Capital, and Eventide Asset Management LLC. Satsuma is headquartered in South San Francisco, California, the US.

Quick View Dihydroergotamine mesylate LOA Data

Report Segments
  • Innovator
Drug Name
  • Dihydroergotamine mesylate
Administration Pathway
  • Nasal
Therapeutic Areas
  • Central Nervous System
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.